Oncology

A novel compound, IRX4204, shows promise in preventing triple-negative breast cancer in lab studies, offering new hope for a safe, effective preventative.

As AI progress stalls on bad data, a new research lab is bringing scientific discipline to the industry's most overlooked and critical pillar.

A new clinic led by one of under 500 board-certified vet oncologists offers Seattle a personalized alternative to corporate pet healthcare.

Advocates call for colorectal cancer screening to start at 45 as cases surge in people under 50, raising questions about Canada's readiness.

A landmark CHF 83.5M deal brings corticorelin, a promising steroid-sparing therapy for brain cancer patients, to Japan, offering a new frontier in care.

As evidence for psychedelic therapy mounts, a key advocacy group brings its case to the UN, challenging decades of prohibitive international drug policy.

Amid fierce competition, Triangle Insights Group hires a seasoned expert to guide clients through the complex world of drug pricing and market access.

In the quest to drug the 'undruggable,' Erasca consolidates worldwide control of its promising pan-RAS inhibitor, setting the stage for a global showdown.

A new AI biomarker analyzes blood vessels in CT scans, offering earlier, more accurate predictions of which patients will benefit from immunotherapy.

Relmada Therapeutics stock skyrockets on promising bladder cancer data and a $160M financing deal, setting a high-stakes stage for its investor conference.

With 8x sales growth and 90% prediction accuracy, AI pioneer QuantHealth is proving that simulating clinical trials can slash pharma's $50B failure rate.

Medicus Pharma's microneedle patch for basal cell carcinoma clears nearly three-quarters of lesions, offering a potential non-surgical alternative to the scalpel.

A new AI signature from Caris Life Sciences aims to guide first-line therapy for a deadly cancer, facing hurdles of clinical validation and adoption.

A year after rebranding from FibroGen, Kyntra Bio's first full-year report will test if its lean strategy can fuel its ambitious oncology pipeline.

With one trial halted and another beginning, the company focuses its cash and hopes on BBI-940, a novel drug targeting a fundamental driver of cancer.

IDEAYA Biosciences begins a key trial for its targeted therapy IDE892, aiming to conquer hard-to-treat tumors and pivoting to focus on its proprietary assets.

French pharma giant Servier acquires Day One Biopharmaceuticals, gaining a breakthrough pediatric cancer drug and signaling a major push into rare oncology.

Allarity Therapeutics lands a crucial $20M debt deal to push its unique ovarian cancer drug, stenoparib, through late-stage trials and extend its runway to 2028.

Australia's TGA approves Claritas iPET™, an AI tool that promises faster, lower-dose PET scans, boosting hospital efficiency and patient safety.

After its public debut, BBOT unveils exciting early data from three unique cancer drugs, including a first in pancreatic cancer, backed by a strong cash runway.